Canada markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
8.51-0.13 (-1.50%)
At close: 04:00PM EST
8.47 -0.04 (-0.47%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close8.64
Open8.60
Bid8.47 x 2900
Ask8.50 x 2200
Day's Range8.45 - 8.72
52 Week Range7.73 - 13.30
Volume8,498,925
Avg. Volume10,511,682
Market Cap9.85B
Beta (5Y Monthly)1.30
PE Ratio (TTM)12.89
EPS (TTM)0.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov. 27, 2017
1y Target Est11.36
  • Motley Fool

    3 Turnaround Stocks That Can Bounce Back Big Time in 2022

    If we strictly looked at the performance of the major U.S. stock indexes, 2021 was a great year. While no investor enjoys seeing their stocks go in reverse, patience has a way of paying off handsomely in the stock market. In 2022, the following trio of turnaround stocks have the catalysts needed to bounce back in a big way.

  • Reuters

    Teva settles shareholder lawsuit over generic drug pricing for $420 million

    (Reuters) -Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs. Teva spokesperson Kelley Dougherty said the "vast majority" of the settlement will be funded by the company's insurers. "This resolution is in the overall best interest of Teva and the patients who continue to rely on us each day for the world’s largest portfolio of generics medicines," Dougherty said in an email.

  • Reuters

    UPDATE 2-Teva settles shareholder lawsuit over generic drug pricing for $420 mln

    Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs. Teva spokesperson Kelley Dougherty said the "vast majority" of the settlement will be funded by the company's insurers. "This resolution is in the overall best interest of Teva and the patients who continue to rely on us each day for the world’s largest portfolio of generics medicines," Dougherty said in an email.